IDEXX Laboratories, Inc.

NasdaqGS:IDXX Stock Report

Market Cap: US$34.5b

IDEXX Laboratories Valuation

Is IDXX undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

0/6

Valuation Score 0/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of IDXX when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: IDXX ($419.83) is trading above our estimate of fair value ($407.83)

Significantly Below Fair Value: IDXX is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for IDXX?

Key metric: As IDXX is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for IDXX. This is calculated by dividing IDXX's market cap by their current earnings.
What is IDXX's PE Ratio?
PE Ratio39.7x
EarningsUS$866.24m
Market CapUS$34.47b

Price to Earnings Ratio vs Peers

How does IDXX's PE Ratio compare to its peers?

The above table shows the PE ratio for IDXX vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average31x
EW Edwards Lifesciences
26.3x1.9%US$40.0b
GEHC GE HealthCare Technologies
22.6x11.5%US$37.4b
RMD ResMed
31.6x11.1%US$34.4b
DXCM DexCom
43.8x16.8%US$29.6b
IDXX IDEXX Laboratories
39.7x9.8%US$34.5b

Price-To-Earnings vs Peers: IDXX is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the peer average (31x).

Price to Earnings Ratio vs Industry

How does IDXX's PE Ratio compare vs other companies in the US Medical Equipment Industry?

4 CompaniesPrice / EarningsEstimated GrowthMarket Cap
MHUA Meihua International Medical Technologies
1.5xn/aUS$12.37m
PAVM PAVmed
0.7x-77.8%US$11.86m
RTSL Rapid Therapeutic Science Laboratories
0.3xn/aUS$18.99k
UTRS Minerva Surgical
n/an/aUS$8.00
No more companies available in this PE range
IDXX 39.7xIndustry Avg. 36.2xNo. of Companies11PE020406080100+
4 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: IDXX is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the US Medical Equipment industry average (36.2x).

Price to Earnings Ratio vs Fair Ratio

What is IDXX's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

IDXX PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio39.7x
Fair PE Ratio32.2x

Price-To-Earnings vs Fair Ratio: IDXX is expensive based on its Price-To-Earnings Ratio (39.7x) compared to the estimated Fair Price-To-Earnings Ratio (32.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst IDXX forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$419.83
US$476.76
+13.6%
11.5%US$566.00US$400.00n/a12
Nov ’25US$417.28
US$491.26
+17.7%
12.1%US$570.00US$400.00n/a12
Oct ’25US$495.42
US$527.18
+6.4%
13.7%US$630.00US$395.00n/a12
Sep ’25US$481.33
US$544.55
+13.1%
11.8%US$630.00US$400.00n/a12
Aug ’25US$477.84
US$554.05
+15.9%
12.4%US$641.00US$400.00n/a12
Jul ’25US$476.40
US$564.14
+18.4%
12.0%US$641.00US$400.00n/a11
Jun ’25US$496.95
US$563.80
+13.5%
11.4%US$641.00US$400.00n/a12
May ’25US$468.04
US$581.97
+24.3%
13.0%US$675.00US$400.00n/a13
Apr ’25US$532.41
US$585.81
+10.0%
12.8%US$675.00US$400.00n/a13
Mar ’25US$576.87
US$583.92
+1.2%
13.3%US$675.00US$400.00n/a12
Feb ’25US$527.28
US$551.04
+4.5%
14.1%US$650.00US$351.00n/a12
Jan ’25US$555.05
US$521.46
-6.1%
13.6%US$600.00US$351.00n/a12
Dec ’24US$482.60
US$510.68
+5.8%
14.7%US$600.00US$351.00n/a11
Nov ’24US$395.35
US$535.74
+35.5%
14.5%US$600.00US$351.00US$417.2811
Oct ’24US$437.27
US$561.19
+28.3%
12.9%US$600.00US$351.00US$495.4211
Sep ’24US$511.29
US$565.74
+10.6%
12.8%US$625.00US$351.00US$481.3311
Aug ’24US$532.30
US$554.36
+4.1%
12.7%US$600.00US$351.00US$477.8411
Jul ’24US$502.23
US$540.80
+7.7%
13.1%US$600.00US$351.00US$476.4010
Jun ’24US$469.84
US$540.80
+15.1%
13.1%US$600.00US$351.00US$496.9510
May ’24US$489.60
US$536.20
+9.5%
14.5%US$600.00US$326.00US$468.0410
Apr ’24US$500.08
US$535.70
+7.1%
14.5%US$600.00US$326.00US$532.4110
Mar ’24US$469.10
US$532.89
+13.6%
14.9%US$600.00US$326.00US$576.879
Feb ’24US$483.20
US$487.89
+1.0%
14.8%US$582.00US$326.00US$527.289
Jan ’24US$407.96
US$463.44
+13.6%
15.3%US$582.00US$326.00US$555.059
Dec ’23US$439.17
US$463.44
+5.5%
15.3%US$582.00US$326.00US$482.609
Nov ’23US$394.93
US$462.56
+17.1%
17.2%US$582.00US$326.00US$395.359

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

Centene

US$29.0b

Operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States.

CNC

US$58.83

7D

-3.2%

1Y

-19.1%

Elevance Health

US$92.9b

Operates as a health benefits company in the United States.

ELV

US$400.70

7D

-5.8%

1Y

-13.9%

CVS Health

US$66.9b

Provides health solutions in the United States.

CVS

US$56.05

7D

0.4%

1Y

-17.9%